Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study
Karen S. Anderson(Institute for Biodiversity), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Julia N. Cheng(Arizona State University), Diego Chowell(Icahn School of Medicine at Mount Sinai), Sara I. Pai(Yale University), Jennifer E. Gerber(Johns Hopkins University), Neil D. Gross(The University of Texas MD Anderson Cancer Center), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), Sailaja Kesiraju(Arizona State University), Rizwan Alam(Arizona State University), Gypsyamber DʼSouza(Johns Hopkins University)
Cited by 42
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
|Journal of Clinical Oncology|2008|1.6k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k